Background: Although cholinesterase inhibitors are used for the treatment of Alzheimer’s disease, the clinical benefits of these drugs are being questioned. Anticholinergic drugs have the opposite pharmacological action to cholinesterase inhibitors, and may antagonize the effects of cholinesterase inhibitors. Therefore, this drug combination should be avoided. Nevertheless, high rates of concurrent use of anticholinergic drugs and cholinesterase inhibitors have been reported in the US. To the authors’ knowledge, use of this inappropriate drug combination has not been studied outside North America.
Objective: To investigate (i) whether anticholinergic drug use is more common among users than non-users of cholinesterase inhibitors, and (ii) which factors are associated with use of anticholinergic drugs among users of cholinesterase inhibitors.
Methods: We analysed data on age, sex, type of residential area (urban/rural) and drugs dispensed for patients aged ≥75 years registered in the Swedish Prescribed Drug Register from October to December 2005 (n = 731 105). The prevalence of use of anticholinergic drugs in users of cholinesterase inhibitors was compared with that in non-users of cholinesterase inhibitors and logistic regression was used to study the association between use of cholinesterase inhibitors and anticholinergic drugs. Logistic regression was also used to analyse whether age, sex, type of residential area or number of dispensed drugs was associated with use of anticholinergic drugs among users of cholinesterase inhibitors (n = 18 326).
Results: Anticholinergic drug use was more common among cholinesterase inhibitor users than non-users, particularly in men, of whom 9% who were taking cholinesterase inhibitors were dispensed anticholinergic drugs compared with 5% who were not taking cholinesterase inhibitors. Use of cholinesterase inhibitors was associated with use of anticholinergic drugs in men (odds ratio 1.23; 95% CI 1.13, 1.35), after adjustment for age, type of residential area and number of dispensed drugs. Male sex and use of many drugs were independently associated with concurrent use of anticholinergic drugs and cholinesterase inhibitors.
Conclusion: Anticholinergic drug use is more common among cholinesterase inhibitor users than non-users, even though anticholinergic drugs may antagonize the effect of cholinesterase inhibitors. Hence, if the true clinical effects of cholinesterase inhibitors are to be accurately assessed, they need to be studied in the absence of anticholinergic drugs.
Dementia Residential Area Cholinesterase Inhibitor Rivastigmine Galantamine
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
This study was supported financially by grants from the Swedish Council for Working Life and Social Research and The Foundation for Geriatric Diseases at Karolinska Institutet. The authors have no conflicts of interest that are directly relevant to the content of this study. The authors thank the Swedish National Board of Health and Welfare for providing data for the study.
Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001; 62Suppl. 21: 11–4PubMedGoogle Scholar
Wilkinson DG, Francis FT, Schwam E, et al. Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004; 21(7): 453–78PubMedCrossRefGoogle Scholar
Olsen CE, Poulsen HD, Lublin HK. Drug therapy of dementia in elderly patients: a review. Nord J Psychiatry 2005; 59(2): 71–7PubMedCrossRefGoogle Scholar
Ringman JM, Cummings JL. Current and emerging pharmacological treatment options for dementia. Behav Neurol 2006; 17(1): 5–16PubMedGoogle Scholar
Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ 2005 Aug 6; 331(7512): 321–7PubMedCrossRefGoogle Scholar
Iliffe S. The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer’s disease. CNS Drugs 2007; 21(3): 177–84PubMedCrossRefGoogle Scholar
Martin RM, Rink E, Wilkinson DG, et al. Did knowledge, opinions, background, and health authority advice influence early prescribing of the novel Alzheimer’s disease drug done-pezil in general practice? National postal survey. Pharmacoepidemiol Drug Saf 1999 Oct; 8(6): 413–22PubMedCrossRefGoogle Scholar
Oude Voshaar RC, Burns A, Olde Rikkert MG. Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs. Int J Geriatr Psychiatry 2006 Jan; 21(1): 29–31PubMedCrossRefGoogle Scholar
Purandare N, Swarbrick C, Fischer A, et al. Cholinesterase inhibitors for Alzheimer’s disease: variations in clinical practice in the north-west of England. Int J Geriatr Psychiatry 2006 Oct; 21(10): 961–4PubMedCrossRefGoogle Scholar
Hansen RA, Gartlehner G, Lohr KN, et al. Functional outcomes of drug treatment in Alzheimer’s disease: a systematic review and meta-analysis. Drugs Aging 2007; 24(2): 155–67PubMedCrossRefGoogle Scholar
Edwards KR, O’Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc 2002 Jun; 50(6): 1165–6PubMedCrossRefGoogle Scholar
Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006 Feb 25; 332(7539): 455–9PubMedCrossRefGoogle Scholar
Chutka DS, Takahashi PY, Hoel RW. Inappropriate medications for elderly patients. Mayo Clin Proc 2004 Jan; 79(1): 122–39PubMedCrossRefGoogle Scholar
Carnahan RM, Lund BC, Perry PJ, et al. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc 2004 Dec; 52(12): 2082–7PubMedCrossRefGoogle Scholar
Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc 2002 May; 50(5): 836–42PubMedCrossRefGoogle Scholar
Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005 Apr 11; 165(7): 808–13PubMedCrossRefGoogle Scholar
Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register: opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007 Jul; 16(7): 726–35PubMedCrossRefGoogle Scholar
WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway. About the ATC/DDD system [online]. Available from URL: http://www.whocc.no/atcddd/ [Accessed 2007 Apr 19]
Lau HS, de Boer A, Beuning KS, et al. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997 May; 50(5): 619–25PubMedCrossRefGoogle Scholar
Hardell L, Carlberg M, Hansson Mild K. Use of cellular telephones and brain tumour risk in urban and rural areas. Occup Environ Med 2005 Jun; 62(6): 390–4PubMedCrossRefGoogle Scholar
Skelly J, Flint AJ. Urinary incontinence associated with dementia. J Am Geriatr Soc 1995 Mar; 43(3): 286–94PubMedGoogle Scholar
Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry 2003 Jul–Aug; 11(4): 458–61PubMedGoogle Scholar
Jewart RD, Green J, Lu CJ, et al. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry 2005 Apr; 13(4): 324–8PubMedGoogle Scholar
Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001 Nov 1; 154(9): 854–64PubMedCrossRefGoogle Scholar